|
Comparative Study of Efficacy and Safety of Clopidogrel Versus Prasugrel in Patient with Acute Coronary Syndrome
|
|
| Author:
|
UPLOADED BY-ADMIN, NIKI V. MODI, INDERMEET S. ANAND
|
| Abstract:
|
The aim of the study was to compare efficacy and safety of prasugrel, a new thienopyridine, versus clopidogrel in
patient with acute coronary syndrome for this we randomly assigned 48 patients with moderate-to-high-risk acute coronary
syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily
maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 2 months. The primary
efficacy end point was reduction in risk of the occurrence of cardiovascular death, myocardial infarction, or stroke & rehospitalization
for recurrent Unstable Angina (Efficacy end point) and reduction in risk of haemorrhage (Safety end point).
While the Secondary end points were Platelet aggregation measures. From result of our study it was observed that prasugrel
was superior in terms of efficacy and safety as compared to clopidogrel except the bleeding event which was found higher in
prasugrel group. Thus the superiority of both the loading dose and maintenance dose of prasugrel compared with the
standard dose of clopidogrel emphasizes the benefits of high level of inhibition of platelet aggregation by P2Y12 receptor
inhibition prevents the cardiac events in patient of acute coronary syndrome. The greatest risk of the more aggressive
antiplatelet regimen with prasugrel is bleeding. So efforts to minimize the risk of excess bleeding with prasugrel are needed.
Although our results suggest that prasugrel seems to be a better option than clopidogrel, long term studies with a larger
population size and for a longer follow up duration are required to confirm the superiority of prasugrel as compared to
clopidogrel in Indian patients with acute coronary syndrome.
|
| Keyword:
|
Acute Coronary Syndrome; Prasugrel; Clopidogrel
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|